BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lantus insulin glargine: Postmarketing study data

Researchers at Lund University reported data from an analysis of the Swedish national drug prescription registry showing that use of the diabetes drug Lantus almost doubled the risk for developing cancer, whereas use of metformin led to an 8% lower risk of cancer in patients with diabetes. Data were presented at the San Antonio...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >